0000000000305693
AUTHOR
Bruno Guerci
showing 3 related works from this author
Pragmatic Diabetes Management in Nursing Homes: Individual Care Plan
2013
Although the management of diabetes as a simple entity has been extensively developed, there is a dearth of evidence in elderly, frail patients with multiple comorbidities and polymedication. This population represents a large proportion of the residents of nursing homes (NHs). As a multidisciplinary group of French experts (geriatricians, endocrinologists, diabetologists, and general practitioners) with practical experience in this area, which is growing in magnitude throughout the world, we convened to compile pragmatic, simple advice on the management of elderly, frail diabetic patients. Given demands on NH personnel (manager, medical coordinator, nurses, and, at the front line of care p…
Prise en charge pragmatique du diabétique en EHPAD
2014
Resume On estime a 20 a 30 % le pourcentage de residents en Etablissement d’Hebergement pour Personnes Âgees Dependantes (EHPAD) qui presentent un diabete sucre. Il s’agit souvent de patients lourds, fragiles, polypathologiques, parfois atteints de troubles cognitifs majeurs. A ces âges, et dans ce contexte, le controle strict du diabete passe au second plan par rapport a la prevention des risques de chute, de denutrition, de sarcopenie et de declin cognitif, ainsi qu’a la prevention des accidents metaboliques aigus. La redaction d’un Plan de Soins Personnalise permet de fixer les objectifs a atteindre pour un patient donne, d’adapter le traitement antidiabetique au cas par cas, et de preci…
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-…
2017
Background Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes. Methods DEPICT-1 was a double-blind, randomised, parallel-controlled, three-arm, phase 3, multicentre study done at 143 sites in 17 countries. Eligible patients were aged 18–75 years and had inadequately controlled type 1 diabetes (HbA1c between ≥7·7% and ≤11·0% [≥61·0 mmol/mol and ≤97·0 mmol/mol]) and had been prescribed insulin for at least 12 months before enrolment. After an 8 week lead-in period to optimise diabetes man…